Wire · opportunities
Muk Hyun-sang, who led the 2.2 trillion won national new drug R&D, appointed as CEO of ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 13 August 2026 · Fusion42 review
Muk Hyun-sang, who led the national drug R&D project with a budget of approximately 2.2 trillion won, has been appointed CEO of Newpass Bio. The company aims to move its drug pipelines from research to commercialisation, focusing on osteoarthritis, autoimmune diseases, immuno-oncology, and expanding cartilage regeneration technology into pet pharmaceuticals.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your biotech venture faces a shift from research to commercial drug development led by a proven executive with massive national R&D experience. Expansion into pet pharmaceuticals opens a new adjacent market to pursue immediately.
◆ Coverage
1 source · 13 Aug 2026
◆ Related on Wire
◆ Topics